MOBI earnings analysis
What we found in MOBI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Mobia Medical delivered strong Q2 top-line momentum, with revenue of $13.5 million, up 102% year over year, and gross margin of 83.2%. However, operating expenses rose 83% to $29.2 million, producing a $21.0 million net loss and $(1.10) EPS, while the company also reported an ineffective control environment tied to EPS calculations. The $134.0 million of IPO net proceeds improves liquidity, but ongoing losses, elevated spending and the unremediated material weakness keep the overall sentiment neutral.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue doubled and beat consensus
- Q2 revenue was $13.5 million, up 102% year over year and $1.1 million above the $12.38 million consensus estimate.
- Gross margin reached 83.2%
- Gross margin expanded to 83.2% in Q2, indicating strong underlying product economics despite the quarterly loss.
- IPO materially strengthened liquidity
- The May 11, 2026 IPO generated approximately $134.0 million of net proceeds after $10.5 million of underwriting discounts and commissions and $5.5 million of offering expenses.
- IPO proceeds remain largely liquid
- Management stated that IPO proceeds were invested primarily in savings and money market accounts, with no material change to the expected use of proceeds described in the prospectus.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Expense growth exceeds revenue growth
- Operating expenses increased 83% to $29.2 million, substantially outpacing revenue growth and contributing to a net loss of $21.0 million and EPS of $(1.10).
- Unremediated material weakness
- Management concluded that disclosure controls and procedures were not effective as of June 30, 2026 because of a material weakness involving review of inputs used to calculate net loss per share.
- Prior-period EPS reporting risk
- The material weakness caused a revision to the weighted-average share count and net loss per share for the year ended December 31, 2025; management said it will not be considered remediated until the control operates effectively for a sufficient period.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.1
- Gross margin
- 83.2%
What they said about what is next.
The supplied 10-Q text does not include quantitative guidance. The related earnings disclosure cites 2026 revenue guidance of $54.0 million to $56.0 million, but does not establish whether that outlook changed versus the prior outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · June 4, 2026
- MOBI reported a strong Q1 2026 performance with a 113.3% increase in revenue to $12.1 million compared to the same period last year, primarily driven by growing adoption of its Vivistim System. While gross margin…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MOBI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever